Recent development of BTK-based dual inhibitors in the treatment of cancers

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Bruton's tyrosine kinase (BTK) is a key target for cancer therapy.
• Current BTK inhibitors show promise but face challenges like drug resistance.
• Dual inhibitors offer a strategy to overcome limitations of single-target therapies.

Purpose of the Study:

• To review the scientific rationale and development of BTK-based dual inhibitors.
• To summarize the current status of these agents in preclinical and clinical research.
• To discuss future directions for BTK-based dual inhibitor drug design.

Main Methods:

• Literature review of scientific background and theoretical basis for BTK dual inhibitors.
• Analysis of preclinical and clinical study data for BTK-based dual agents.
• Discussion of emerging trends and future research opportunities.

Main Results:

• BTK-based dual inhibitors are a feasible strategy for treating refractory and drug-resistant tumors.
• Advances in this field provide a foundation for future drug development.
• Significant progress is anticipated in novel dual inhibitor design and clinical trials.

Conclusions:

• BTK-based dual inhibitors represent a promising therapeutic approach for challenging cancers.
• Further research and development are expected to yield potent new treatments.
• This strategy holds potential for overcoming drug resistance in various malignancies.